{"prompt": "['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 49 of 122', 'Severity of anaphylaxis will be graded according to the European Academy of Allergy and', 'Clinical Immunology (EAACI) guidelines (Table 10; adapted from Muraro, 2007). The', 'clinical assessment of anaphylaxis is described in Section 8.5.1.1.', 'Table 10: EAACI Severity Grading System for Anaphylaxis', 'Grade 1', 'Grade 2', 'Grade 3', 'Mild', 'Moderate', 'Severe', 'Skin and subcutaneous tissues', 'Features suggesting respiratory,', 'Hypoxia, hypotension, or', 'only', 'cardiovascular, or', 'neurologic compromise', 'gastrointestinal involvement', 'Generalized erythema, urticaria,', 'Dyspnea, stridor, wheeze,', 'Cyanosis or SpO292% at any', 'periorbital edema or angioedema', 'nausea, vomiting, dizziness', 'stage, hypotension (systolic', '(presyncope), diaphoresis, chest', 'blood pressure < 90 mm Hg in', 'or throat tightness, or abdominal', 'adults), confusion, collapse, loss', 'pain', 'of consciousness, or', 'incontinence', 'Source: Adapted from Muraro, 2007.', 'EAACI; European Academy of Allergy and Clinical Immunology.', 'Severity of all other adverse events will be graded according to the National Cancer Institute', '(NCI) Common Terminology Criteria for Adverse Events (CTCAE). CTCAE terms are', 'grouped by system organ class, graded 1 to 5, and have unique clinical descriptions of', 'severity for each adverse event based on the general guideline presented in Table 11.', 'Table 11: NCI CTCAE Severity Grading System for Adverse Events', 'Grade 1', 'Grade 2', 'Grade 3', 'Grade 4', 'Grade 5', 'Mild', 'Moderate', 'Severe', 'Life-Threatening', 'Death', 'Asymptomatic or', 'Minimal, local, or', 'Severe or medically', 'Life-threatening', 'Death', 'mild symptoms;', 'noninvasive', 'significant but not', 'consequences;', 'related to', 'clinical or diagnostic', 'intervention', 'immediately', 'urgent intervention', 'adverse', 'observations only;', 'indicated; limiting', 'life-threatening;', 'indicated', 'event', 'intervention not', 'age-appropriate', 'hospitalization or', 'indicated', 'instrumental', 'prolongation of', 'activities of daily', 'hospitalization', 'living', 'indicated; disabling;', 'limiting self-care', 'activities of daily', 'living', 'Source: NCI CTCAE.', 'NCI CTCAE, National Cancer Institute Common Terminology Criteria for Adverse Events.']['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 50 of 122', '8.5 Special Safety Considerations', 'This section provides guidelines for the assessment of allergic reactions (including', 'assessment of anaphylaxis and tolerability of a dose), treatment of allergic reactions, study', 'product dose adjustments due to allergic reactions or other reasons, missed doses of study', 'product, adverse events of interest, and other notable events (overdose, pregnancy and other', 'reproductive considerations). The assessment and treatment of allergic reactions resulting', 'from accidental and nonaccidental food allergen exposure should follow the same guidelines', 'as allergic reactions resulting from study product.', '8.5.1', 'Assessment of Allergic Reactions', 'Allergy symptoms may occur during AR101 treatment as observed in other desensitization', 'protocols. Subjects must be observed for at least 90 minutes after completion of a dose or', 'dose escalation at the study site, with vital sign measurements (blood pressure and heart rate)', 'and assessment for symptoms of allergic reaction performed every 30 minutes. The postdose', 'observation period may be shortened to 30 minutes during maintenance if no allergy', 'symptoms occurred during the previous 3 maintenance visits.', 'The length of observation will be extended beyond 90 minutes if symptoms of allergic', 'reaction develop as follows:', 'Mild symptoms: observe for 90 minutes or at least 1 hour after symptoms resolve,', 'whichever is longer.', 'Moderate symptoms: observe for at least 2 hours after symptoms resolve.', 'Severe symptoms: observe for at least 3 hours after symptoms resolve either at the', 'study site or an emergency facility, as appropriate. Consider extended overnight', 'observation for subjects experiencing protracted symptoms.', 'The assessing physician will determine whether the allergy symptoms meet the criteria for', 'dose-limiting symptoms (Section 8.5.1.2).', 'The severity of symptoms of an allergic reaction will be assessed as described in Section 8.4.', 'Signs and symptoms of allergic reactions will be recorded on the case report form and in the', \"subject's source documents.\", '8.5.1.1', 'Assessment of Anaphylaxis', 'Anaphylaxis is defined by a number of signs and symptoms, alone or in combination, that', 'occur within minutes up to a few hours after exposure to a provoking agent. Anaphylaxis', 'can be mild, moderate, or severe (Section 8.4). Adverse events of anaphylaxis are considered', 'adverse events of interest and require rapid reporting as described in Section 8.6.2.']\n\n###\n\n", "completion": "END"}